Gokengin Deniz, Bursa Dominik, Skrzat-Klapaczynska Agata, Alexiev Ivailo, Arsikj Elena, Balayan Tatevik, Begovac Josip, Cicic Alma, Dragovic Gordana, Harxhi Arjan, Aimla Kerstin, Lakatos Botond, Matulionyte Raimonda, Mulabdic Velida, Oprea Cristiana, Papadopoulos Antonios, Rukhadze Nino, Sedlacek Dalibor, Sojak Lubomir, Tomazic Janez, Vassilenko Anna, Vasylyev Marta, Verhaz Antonija, Yancheva Nina, Yurin Oleg, Kowalska Justyna
Department of Infectious Diseases and Clinical Microbiology, Medical Faculty, Ege University, Izmir 35100, Türkiye.
HIV/AIDS Research and Practice Center, Ege University, Izmir 35100, Türkiye.
Vaccines (Basel). 2023 Jan 4;11(1):122. doi: 10.3390/vaccines11010122.
With no expected vaccine for HIV in the near future, we aimed to define the current situation and challenges for pre- and post-exposure prophylaxis (PrEP and PEP) in Central and Eastern Europe (CEE). The Euroguidelines CEE Network Group members were invited to respond to a 27-item survey including questions on PrEP (response rate 91.6%). PrEP was licensed in 68.2%; 95 centers offered PrEP and the estimated number on PrEP was around 9000. It was available in daily (40.1%), on-demand (13.3%), or both forms (33.3%). The access rate was <1−80%. Three major barriers for access were lack of knowledge/awareness among people who are in need (59.1%), not being reimbursed (50.0%), and low perception of HIV risk (45.5%). Non-occupational PEP was available in 86.4% and was recommended in the guidelines in 54.5%. It was fully reimbursed in 36.4%, only for accidental exposures in 40.9%, and was not reimbursed in 22.72%. Occupational PEP was available in 95.5% and was reimbursed fully. Although PrEP scale-up in the region has gained momentum, a huge gap exists between those who are in need of and those who can access PrEP. Prompt action is required to address the urgent need for PrEP scale-up in the CEE region.
由于近期预计不会有针对艾滋病毒的疫苗,我们旨在明确中东欧地区暴露前预防(PrEP)和暴露后预防(PEP)的现状及挑战。邀请了欧洲指南中东欧网络小组成员回答一份包含27个问题的调查问卷,其中包括关于PrEP的问题(回复率为91.6%)。PrEP在68.2%的地区获得许可;95个中心提供PrEP,接受PrEP治疗的估计人数约为9000人。PrEP有每日服用(40.1%)、按需服用(13.3%)或两种方式结合(33.3%)的形式。其可及率为<1−80%。三个主要的获取障碍是有需求者缺乏知识/意识(59.1%)、未获报销(50.0%)以及对艾滋病毒风险的认知度低(45.5%)。86.4%的地区提供非职业性PEP,其中54.5%在指南中被推荐。36.4%的地区可全额报销,40.9%仅针对意外暴露可报销,22.72%的地区不予报销。95.5%的地区提供职业性PEP且可全额报销。尽管该地区PrEP的推广已取得进展,但在有需求者和能够获取PrEP者之间仍存在巨大差距。需要迅速采取行动来满足中东欧地区扩大PrEP使用的迫切需求。